Modify Therapy/Monitor Closely.iloperidone and trazodone both increase sedation. Use Caution/Monitor.iloperidone increases levels of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.imatinibtrazodone will decrease the level or effect of imatinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.imipramineimipramine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.imipramine and trazodone both increase sedation. Use Caution/Monitor.indinavirindinavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.trazodone will decrease the level or effect of indinavir by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.indomethacintrazodone, indomethacin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ipratropiumipratropium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.irinotecan liposomaltrazodone will decrease the level or effect of irinotecan liposomal by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.isavuconazonium sulfatetrazodone will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.isoniazidisoniazid will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.trazodone and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.isoproterenoltrazodone increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.istradefyllineistradefylline will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.itraconazoletrazodone will decrease the level or effect of itraconazole by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.ivermectintrazodone will decrease the level or effect of ivermectin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.ketamineketamine and trazodone both increase sedation. Use Caution/Monitor.ketoprofentrazodone, ketoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ketorolactrazodone, ketorolac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ketorolac intranasaltrazodone, ketorolac intranasal. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ketotifen, ophthalmictrazodone and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.L-tryptophantrazodone and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.lapatiniblapatinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.trazodone will decrease the level or effect of lapatinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.trazodone and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.lasmiditanlasmiditan, trazodone. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.lemborexanttrazodone will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification.lenacapavirlenacapavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.lenvatinibtrazodone and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.leuprolideleuprolide increases toxicity of trazodone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.levalbuteroltrazodone increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.levofloxacintrazodone and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.levorphanollevorphanol and trazodone both increase sedation. Use Caution/Monitor.linagliptintrazodone will decrease the level or effect of linagliptin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Use of alternative treatments is strongly recommended when linagliptin is to be administered with a P-gp inducer.lisdexamfetaminetrazodone increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.lithiumtrazodone and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lofepraminelofepramine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.lofepramine and trazodone both increase sedation. Use Caution/Monitor.lofexidinetrazodone and lofexidine both increase sedation. Use Caution/Monitor.trazodone decreases effects of lofexidine by unspecified interaction mechanism. Use Caution/Monitor.lomitapidetrazodone increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.loperamidetrazodone will decrease the level or effect of loperamide by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.loprazolamloprazolam and trazodone both increase sedation. Use Caution/Monitor.lorazepamlorazepam and trazodone both increase sedation. Use Caution/Monitor.lorlatiniblorlatinib will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lormetazepamlormetazepam and trazodone both increase sedation. Use Caution/Monitor.lornoxicamtrazodone, lornoxicam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.lovastatintrazodone will decrease the level or effect of lovastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.loxapineloxapine and trazodone both increase sedation. Use Caution/Monitor.loxapine inhaledloxapine inhaled and trazodone both increase sedation. Use Caution/Monitor.lsdtrazodone and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.lumefantrinelumefantrine will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lurasidonelurasidone, trazodone. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.maprotilinemaprotiline and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.maprotiline and trazodone both increase sedation. Use Caution/Monitor.maraviroctrazodone will decrease the level or effect of maraviroc by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.marijuanamarijuana will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.trazodone and marijuana both increase sedation. Use Caution/Monitor.meclizinemeclizine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.meclofenamatetrazodone, meclofenamate. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.mefenamic acidtrazodone, mefenamic acid. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.melatonintrazodone and melatonin both increase sedation. Use Caution/Monitor.meloxicamtrazodone, meloxicam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.meperidinemeperidine and trazodone both increase sedation. Use Caution/Monitor.meprobamatetrazodone and meprobamate both increase sedation. Use Caution/Monitor.mestranoltrazodone will decrease the level or effect of mestranol by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.metaproterenoltrazodone increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.metaxalonemetaxalone and trazodone both increase sedation. Use Caution/Monitor.methadonetrazodone and methadone both increase QTc interval. Modify Therapy/Monitor Closely.methadone and trazodone both increase sedation. Use Caution/Monitor.methamphetaminetrazodone increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. trazodone increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Significant - Monitor Closely..methamphetamine increases toxicity of trazodone by Other (see comment). Use Caution/Monitor. Comment: Amphetamines may increase the toxicity of serotonin modulators, increasing the risk of serotonin syndrome. .methocarbamolmethocarbamol and trazodone both increase sedation. Use Caution/Monitor.methscopolaminemethscopolamine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.methylenedioxymethamphetaminetrazodone increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methylphenidatemethylphenidate increases toxicity of trazodone by Other (see comment). Modify Therapy/Monitor Closely. Comment: Methylphenidate may increase serotonin release of agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity.methylprednisolonemethylprednisolone will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.trazodone will decrease the level or effect of methylprednisolone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.metronidazolemetronidazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.miconazole vaginalmiconazole vaginal will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.midazolammidazolam and trazodone both increase sedation. Use Caution/Monitor.midazolam intranasaltrazodone will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation.midodrinetrazodone increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.mipomersenmipomersen, trazodone. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.mirtazapinetrazodone and mirtazapine both increase sedation. Use Caution/Monitor.trazodone and mirtazapine both increase serotonin levels. Modify Therapy/Monitor Closely.mitotanemitotane decreases levels of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.modafiniltrazodone increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.morphinemorphine and trazodone both increase sedation. Use Caution/Monitor.trazodone and morphine both increase serotonin levels. Modify Therapy/Monitor Closely.motherworttrazodone and motherwort both increase sedation. Use Caution/Monitor.moxonidinetrazodone and moxonidine both increase sedation. Use Caution/Monitor.nabilonetrazodone and nabilone both increase sedation. Use Caution/Monitor.nabumetonetrazodone, nabumetone. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.nafcillinnafcillin will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nalbuphinenalbuphine and trazodone both increase sedation. Use Caution/Monitor.naproxentrazodone, naproxen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.naratriptannaratriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.nefopamnefopam, trazodone. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Use combination with caution.nelfinavirnelfinavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.trazodone will decrease the level or effect of nelfinavir by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.neomycin POtrazodone will decrease the level or effect of neomycin PO by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.nifedipinenifedipine will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nilotinibnilotinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.trazodone will decrease the level or effect of nilotinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.nirmatrelvirnirmatrelvir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adverse reactions of nausea, dizziness, hypotension, and syncope observed following coadministration of trazodone and strong CYP3A4 inhibitors. Consider lower trazodone dose.nirmatrelvir/ritonavirnirmatrelvir/ritonavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adverse reactions of nausea, dizziness, hypotension, and syncope observed following coadministration of trazodone and strong CYP3A4 inhibitors. Consider lower trazodone dose.norepinephrinetrazodone increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trazodone increases effects of norepinephrine by unknown mechanism. Use Caution/Monitor.nortriptylinenortriptyline and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.nortriptyline and trazodone both increase sedation. Use Caution/Monitor.ofloxacintrazodone and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.olanzapineolanzapine and trazodone both increase sedation. Use Caution/Monitor.oliceridinetrazodone will increase the level or effect of oliceridine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. trazodone, oliceridine. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely.opium tinctureopium tincture and trazodone both increase sedation. Use Caution/Monitor.orphenadrinetrazodone and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.orphenadrine and trazodone both increase sedation. Use Caution/Monitor.osilodrostatosilodrostat and trazodone both increase QTc interval. Use Caution/Monitor.oxaliplatinoxaliplatin will increase the level or effect of trazodone by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.oxaprozintrazodone, oxaprozin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.oxazepamoxazepam and trazodone both increase sedation. Use Caution/Monitor.oxcarbazepineoxcarbazepine will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.oxybutyninoxybutynin and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutynin topicaloxybutynin topical and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutynin transdermaloxybutynin transdermal and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.oxycodoneoxycodone and trazodone both increase sedation. Use Caution/Monitor.oxymorphoneoxymorphone and trazodone both increase sedation. Use Caution/Monitor.paclitaxeltrazodone will decrease the level or effect of paclitaxel by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.paclitaxel protein boundtrazodone will decrease the level or effect of paclitaxel protein bound by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.paliperidonetrazodone will decrease the level or effect of paliperidone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.trazodone and